# ZENITH20 (NCT03318939)

> Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

No report yet. It can be ordered.

- Drugs tested: poziotinib

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03318939
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: Spectrum Pharmaceuticals, Inc
- Conditions: NSCLC
- Interventions: Poziotinib
- Enrollment: 648
- Primary outcome: Objective Response Rate (ORR)

## Indexed commentary on ZENITH20 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 5
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=zenith20-nct03318939